C-Rad AB (publ) (CRAD-B.ST)
SEK 29.9
(-0.17%)
SEK 29.9
(-0.17%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 3.8 Million SEK | -97.93% |
| 2022 | 183.54 Million SEK | 37.32% |
| 2021 | 133.66 Million SEK | 14.42% |
| 2020 | 116.82 Million SEK | -13.81% |
| 2019 | 135.54 Million SEK | 22.64% |
| 2018 | 110.51 Million SEK | 19.86% |
| 2017 | 92.2 Million SEK | 13.87% |
| 2016 | 80.97 Million SEK | 32.39% |
| 2015 | 61.16 Million SEK | 16.94% |
| 2014 | 52.3 Million SEK | 5.23% |
| 2013 | 49.7 Million SEK | 46.47% |
| 2012 | 33.93 Million SEK | -38.07% |
| 2011 | 54.79 Million SEK | 121.22% |
| 2010 | 24.76 Million SEK | 27.99% |
| 2009 | 19.35 Million SEK | -4.48% |
| 2008 | 20.26 Million SEK | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 1.3 Million SEK | -18.75% |
| 2024 Q3 | 55.3 Million SEK | 69.23% |
| 2024 Q1 | 1.6 Million SEK | 60.0% |
| 2023 Q1 | 52.7 Million SEK | -23.12% |
| 2023 FY | 3.8 Million SEK | -97.93% |
| 2023 Q4 | 1 Million SEK | -98.25% |
| 2023 Q2 | 52.2 Million SEK | -0.95% |
| 2023 Q3 | 57.3 Million SEK | 9.77% |
| 2022 Q3 | 39.1 Million SEK | -2.01% |
| 2022 Q1 | 36 Million SEK | -9.92% |
| 2022 Q2 | 39.9 Million SEK | 10.83% |
| 2022 FY | 183.54 Million SEK | 37.32% |
| 2022 Q4 | 68.54 Million SEK | 75.31% |
| 2021 Q3 | 31.5 Million SEK | -1.56% |
| 2021 FY | 133.66 Million SEK | 14.42% |
| 2021 Q2 | 32 Million SEK | 1.91% |
| 2021 Q1 | 31.4 Million SEK | -0.71% |
| 2021 Q4 | 39.96 Million SEK | 26.87% |
| 2020 FY | 116.82 Million SEK | -13.81% |
| 2020 Q3 | 27.7 Million SEK | 4.14% |
| 2020 Q2 | 26.6 Million SEK | -13.92% |
| 2020 Q1 | 30.9 Million SEK | -29.68% |
| 2020 Q4 | 31.62 Million SEK | 14.16% |
| 2019 Q1 | 27.4 Million SEK | -8.42% |
| 2019 Q2 | 31.5 Million SEK | 14.96% |
| 2019 Q3 | 32.7 Million SEK | 3.81% |
| 2019 FY | 135.54 Million SEK | 22.64% |
| 2019 Q4 | 43.94 Million SEK | 34.38% |
| 2018 Q4 | 29.91 Million SEK | 2.81% |
| 2018 Q2 | 26.2 Million SEK | 3.56% |
| 2018 FY | 110.51 Million SEK | 19.86% |
| 2018 Q1 | 25.3 Million SEK | 3.25% |
| 2018 Q3 | 29.1 Million SEK | 11.07% |
| 2017 Q3 | 21.9 Million SEK | -7.16% |
| 2017 Q1 | 22.57 Million SEK | 2.79% |
| 2017 FY | 92.2 Million SEK | 13.87% |
| 2017 Q4 | 24.5 Million SEK | 11.89% |
| 2017 Q2 | 23.58 Million SEK | 4.48% |
| 2016 Q3 | 20.79 Million SEK | 8.52% |
| 2016 Q4 | 21.96 Million SEK | 5.61% |
| 2016 FY | 80.97 Million SEK | 32.39% |
| 2016 Q1 | 18.33 Million SEK | 26.83% |
| 2016 Q2 | 19.16 Million SEK | 4.52% |
| 2015 Q1 | 13.29 Million SEK | -23.04% |
| 2015 FY | 61.16 Million SEK | 16.94% |
| 2015 Q4 | 14.45 Million SEK | -12.84% |
| 2015 Q3 | 16.58 Million SEK | -1.42% |
| 2015 Q2 | 16.82 Million SEK | 26.54% |
| 2014 Q1 | 10.85 Million SEK | -24.87% |
| 2014 Q3 | 11.15 Million SEK | -14.0% |
| 2014 FY | 52.3 Million SEK | 5.23% |
| 2014 Q4 | 17.27 Million SEK | 54.87% |
| 2014 Q2 | 12.97 Million SEK | 19.51% |
| 2013 FY | 49.7 Million SEK | 46.47% |
| 2013 Q1 | 10.71 Million SEK | 21.09% |
| 2013 Q2 | 13.73 Million SEK | 28.19% |
| 2013 Q3 | 10.81 Million SEK | -21.27% |
| 2013 Q4 | 14.44 Million SEK | 33.62% |
| 2012 Q1 | 7.93 Million SEK | -71.34% |
| 2012 FY | 33.93 Million SEK | -38.07% |
| 2012 Q4 | 8.84 Million SEK | 7.28% |
| 2012 Q3 | 8.24 Million SEK | -8.83% |
| 2012 Q2 | 9.04 Million SEK | 13.94% |
| 2011 Q1 | 8.77 Million SEK | 21.81% |
| 2011 Q4 | 27.7 Million SEK | 251.63% |
| 2011 Q2 | 10.44 Million SEK | 19.04% |
| 2011 Q3 | 7.87 Million SEK | -24.54% |
| 2011 FY | 54.79 Million SEK | 121.22% |
| 2010 Q2 | 6.96 Million SEK | 24.5% |
| 2010 Q3 | 5 Million SEK | -28.09% |
| 2010 Q1 | 5.59 Million SEK | 21.18% |
| 2010 FY | 24.76 Million SEK | 27.99% |
| 2010 Q4 | 7.2 Million SEK | 43.76% |
| 2009 Q3 | 3.65 Million SEK | -32.89% |
| 2009 Q2 | 5.45 Million SEK | -3.08% |
| 2009 Q1 | 5.62 Million SEK | -2.46% |
| 2009 FY | 19.35 Million SEK | -4.48% |
| 2009 Q4 | 4.61 Million SEK | 26.19% |
| 2008 FY | 20.26 Million SEK | 0.0% |
| 2008 Q2 | 4.84 Million SEK | 3.75% |
| 2008 Q1 | 4.66 Million SEK | 0.0% |
| 2008 Q3 | 4.99 Million SEK | 3.12% |
| 2008 Q4 | 5.76 Million SEK | 15.5% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Acarix AB (publ) | 82.85 Million SEK | 95.413% |
| ADDvise Group AB (publ) | 611.8 Million SEK | 99.379% |
| ADDvise Group AB (publ) | 611.8 Million SEK | 99.379% |
| Arcoma AB | 53.25 Million SEK | 92.864% |
| Bactiguard Holding AB (publ) | 4.96 Million SEK | 23.526% |
| BICO Group AB (publ) | 2.84 Billion SEK | 99.867% |
| Boule Diagnostics AB (publ) | 210.44 Million SEK | 98.194% |
| CellaVision AB (publ) | 295.99 Million SEK | 98.716% |
| Clinical Laserthermia Systems AB (publ) | 68.93 Million SEK | 94.487% |
| Chordate Medical Holding AB (publ) | 1.3 Million SEK | -190.257% |
| Duearity AB (publ) | 21.58 Million SEK | 82.395% |
| Dignitana AB (publ) | 74.73 Million SEK | 94.915% |
| Episurf Medical AB (publ) | 2.7 Million SEK | -40.741% |
| Getinge AB (publ) | 10.75 Billion SEK | 99.965% |
| Scandinavian Real Heart AB (Publ) | 18.22 Million SEK | 79.154% |
| Iconovo AB (publ) | 63.35 Million SEK | 94.002% |
| Integrum AB (publ) | 90.57 Million SEK | 95.804% |
| Luxbright AB (publ) | 23.09 Million SEK | 83.543% |
| Mentice AB (publ) | 237.06 Million SEK | 98.397% |
| OssDsign AB (publ) | 175.6 Million SEK | 97.836% |
| Paxman AB (publ) | 133.8 Million SEK | 97.16% |
| Promimic AB (publ) | 48.55 Million SEK | 92.173% |
| Qlife Holding AB (publ) | 162.38 Million SEK | 97.66% |
| SciBase Holding AB (publ) | 69.97 Million SEK | 94.57% |
| ScandiDos AB (publ) | 61.03 Million SEK | 93.774% |
| Sectra AB (publ) | 39.06 Million SEK | 90.272% |
| Sedana Medical AB (publ) | 174.52 Million SEK | 97.823% |
| Senzime AB (publ) | 141.51 Million SEK | 97.315% |
| SpectraCure AB (publ) | 12.12 Million SEK | 68.668% |
| Stille AB | 87.21 Million SEK | 95.643% |
| Vitrolife AB (publ) | 5.56 Billion SEK | 99.932% |
| Xvivo Perfusion AB (publ) | 440.92 Million SEK | 99.138% |